Poor survival in prostate cancer patients with primary refractoriness to docetaxel

Eur Urol. 2014 Feb;65(2):505-7. doi: 10.1016/j.eururo.2013.10.037. Epub 2013 Nov 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Docetaxel
  • Drug Resistance, Neoplasm*
  • Humans
  • Male
  • Multivariate Analysis
  • Prognosis
  • Proportional Hazards Models
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Retrospective Studies
  • Risk Factors
  • Taxoids / therapeutic use*
  • Time Factors

Substances

  • Antineoplastic Agents
  • Taxoids
  • Docetaxel